 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 October 1994 | Volume 121 Issue 7 | Pages 529-535
Purpose: To assess the incidence of amiodarone-mediated aggravation of ventricular tachyarrhythmias or the development of new arrhythmias, such as torsade de pointes, in patients with cardiac disease.
Data Sources and Study Selection: A MEDLINE literature search was done to identify articles published during the last 20 years that presented data on amiodarone-associated proarrhythmic events. The articles were divided into three categories: case reports, uncontrolled retrospective studies, and prospective controlled trials. In addition, articles were identified that examined the effects of amiodarone in patients with previously documented drug-induced torsade de pointes.
Results: 65 English-language case reports dealing with torsade de pointes during amiodarone therapy were found in the literature. In many of these cases, other predisposing factors for the development of torsade de pointes were reported. Seventeen studies each reported data from at least 50 patients who were treated with amiodarone for at least 6 months. Of 2878 patients included in these trials, 57 were reported to have a proarrhythmic event while exposed to the drug (an overall incidence of 2%). Torsade de pointes was observed in one third of these patients (an overall incidence of 0.7%). In seven placebo-controlled trials in which the drug was given as monotherapy, amiodarone was not associated with the development of a proarrhythmic event in any patient. Finally, in three reports, 31 patients with previous drug-mediated torsade de pointes were exposed to amiodarone during short- and long-term therapy. In none of these patients did a recurrent episode of torsade de pointes develop, despite the amiodarone-induced prolongation of the QTc interval, which was equivalent to that observed at the time of torsade de pointes during exposure to previous drugs.
Conclusions: Amiodarone appears to be associated with a remarkably low frequency of proarrhythmic events and an incidence of torsade de pointes of less than 1.0%. This low arrhythmogenicity and the negligible negative inotropic effect of the compound constitute properties that make amiodarone particularly useful in treating high-risk patients prone to sudden cardiac death. Its potential to reduce this risk is currently being evaluated in several large prospective trials.
Author and Article Information
From the University of Freiburg, Freiburg, Germany, and the Veterans Affairs Medical Center of West Los Angeles, Los Angeles, California.
REVIEW
Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia
Requests for Reprints: Stefan H. Hohnloser, MD, University of Freiburg, Department of Cardiology, Hugstetterstrasse 55, 79106 Freiburg, Germany.
This article has been cited by other articles:
|
|
 |
|
  J. H. McMahon and M. L. Grayson Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis Am. J. Health Syst. Pharm., April 1, 2008; 65(7): 619 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wu, S. Rajamani, J. C. Shryock, H. Li, J. Ruskin, C. Antzelevitch, and L. Belardinelli Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone Cardiovasc Res, February 1, 2008; 77(3): 481 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hinterseer, M. B. Thomsen, B.-M. Beckmann, A. Pfeufer, R. Schimpf, H.-E. Wichmann, G. Steinbeck, M. A. Vos, and S. Kaab Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study Eur. Heart J., January 2, 2008; 29(2): 185 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Moro, M. Ferreiro, D. Celestino, E. Medei, M. V. Elizari, and S. Sicouri In Vitro Effects of Acute Amiodarone and Dronedarone on Epicardial, Endocardial, and M Cells of the Canine Ventricle Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2007; 12(4): 314 - 321. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Plakogiannis and R. Ginzburg Possible Amiodarone Warfarin Interaction: A Reemphasis on a Potentially Dangerous Drug Drug Interaction Journal of Pharmacy Practice, December 1, 2007; 20(6): 469 - 473. [Abstract] [PDF]
|
|
|
|
 |
|
 B. N. Singh, S. J. Connolly, H. J.G.M. Crijns, D. Roy, P. R. Kowey, A. Capucci, D. Radzik, E. M. Aliot, S. H. Hohnloser, and the EURIDIS and ADONIS Investigators Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter N. Engl. J. Med., September 6, 2007; 357(10): 987 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Celestino, E. Medei, S. Moro, M. V. Elizari, and S. Sicouri Acute In Vitro Effects of Dronedarone, an Iodine-Free Derivative, and Amiodarone, on the Rabbit Sinoatrial Node Automaticity: A Comparative Study Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 248 - 257. [Abstract] [PDF]
|
|
|
|
 |
|
 B. N. Singh and E. Aliot Newer antiarrhythmic agents for maintaining sinus rhythm in atrial fibrillation: simplicity or complexity? Eur. Heart J. Suppl., September 1, 2007; 9(suppl_G): G17 - G25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Shantsila, T. Watson, and G. Y. Lip Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias Europace, September 1, 2007; 9(suppl_4): iv37 - iv44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Lim, H.-N. Pak, J. C. Ahn, W. H. Song, and Y.-H. Kim Torsade de pointes induced by short-term oral amiodarone therapy Europace, December 1, 2006; 8(12): 1051 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Waldhauser, M. Torok, H.-R. Ha, U. Thomet, D. Konrad, K. Brecht, F. Follath, and S. Krahenbuhl Hepatocellular Toxicity and Pharmacological Effect of Amiodarone and Amiodarone Derivatives J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1413 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Thomsen, P. G.A. Volders, J. D.M. Beekman, J. Matz, and M. A. Vos Beat-to-Beat Variability of Repolarization Determines Proarrhythmic Outcome in Dogs Susceptible to Drug-Induced Torsades de Pointes J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1268 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Schrickel, J. O. Schwab, A. Yang, H. Bielik, A. Bitzen, B. Luderitz, and T. Lewalter Pro-arrhythmic effects of amiodarone and concomitant rate-control medication Europace, June 1, 2006; 8(6): 403 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Mitchell, D. V. Exner, D. G. Wyse, C. J. Connolly, G. D. Prystai, A. J. Bayes, W. T. Kidd, T. Kieser, J. J. Burgess, A. Ferland, et al. Prophylactic Oral Amiodarone for the Prevention of Arrhythmias That Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: A Randomized Controlled Trial JAMA, December 28, 2005; 294(24): 3093 - 3100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Khalameizer, N. Pancheva, L. Reizin, and I. E. Ovsyshcher "Benign" course and malignant clinical presentations of congenital long QT syndrome Europace, January 1, 2005; 7(1): 50 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zimetbaum and M. E. Josephson Is There a Role for Maintaining Sinus Rhythm in Patients with Atrial Fibrillation? Ann Intern Med, November 2, 2004; 141(9): 720 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Antzelevitch, L. Belardinelli, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, and G. Thomas Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties Circulation, August 24, 2004; 110(8): 904 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, R. J. Goodrow Jr, et al. Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S65 - S83. [Abstract] [PDF]
|
|
|
|
|
|
B. N. Singh and N. Wadhani Antiarrhythmic and Proarrhythmic Properties of QT-Prolonging Antianginal Drugs Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S85 - S97. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. G. Yap and A J. Camm Drug induced QT prolongation and torsades de pointes Heart, November 1, 2003; 89(11): 1363 - 1372. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Letelier, K. Udol, J. Ena, B. Weaver, and G. H. Guyatt Effectiveness of Amiodarone for Conversion of Atrial Fibrillation to Sinus Rhythm: A Meta-analysis Arch Intern Med, April 14, 2003; 163(7): 777 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Using oral amiodarone DTB, February 1, 2003; 41(2): 9 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Eckardt, G. Breithardt, and W. Haverkamp Electrophysiologic Characterization of the Antipsychotic Drug Sertindole in a Rabbit Heart Model of Torsade de Pointes: Low Torsadogenic Potential Despite QT Prolongation J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 64 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Sanoski and J. L. Bauman Clinical Observations With the Amiodarone/Warfarin Interaction : Dosing Relationships With Long-term Therapy Chest, January 1, 2002; 121(1): 19 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Haverkamp, L. Eckardt, G. Monnig, E. Schulze-Bahr, H. Wedekind, P. Kirchhof, F. Haverkamp, and G. Breithardt Clinical aspects of ventricular arrhythmias associated with QT prolongation Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K81 - K88. [Abstract] [PDF]
|
|
|
|
|
|
L. M. Hondeghem, L. Carlsson, and G. Duker Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic Circulation, April 17, 2001; 103(15): 2004 - 2013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Thomas, G. Wendt-Nordahl, K. Röckl, E. Ficker, A. M. Brown, and J. Kiehn High-Affinity Blockade of Human Ether-A-Go-Go-Related Gene Human Cardiac Potassium Channels by the Novel Antiarrhythmic Drug BRL-32872 J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 753 - 761. [Abstract] [Full Text]
|
|
|
|
|
|
T. E. Morey, C. N. Seubert, M. J. P. Raatikainen, A. E. Martynyuk, P. Druzgala, P. Milner, M. D. Gonzalez, and D. M. Dennis Structure-Activity Relationships and Electrophysiological Effects of Short-Acting Amiodarone Homologs in Guinea Pig Isolated Heart J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 260 - 266. [Abstract] [Full Text]
|
|
|
|
|
|
B. N. Singh and J. S. M. Sarma Mechanisms of Action of Antiarrhythmic Drugs Relative to the Origin and Perpetuation of Cardiac Arrhythmias Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 69 - 87. [PDF]
|
|
|
|
|
|
K. Glatter, Y. Yang, K. Chatterjee, G. Modin, J. Cheng, S. Kayser, and M. M. Scheinman Chemical Cardioversion of Atrial Fibrillation or Flutter With Ibutilide in Patients Receiving Amiodarone Therapy Circulation, January 16, 2001; 103(2): 253 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D Walker, C. B Singleton, H. Tie, J. A Bursill, K. R Wyse, S. M Valenzuela, S. N Breit, and T. J Campbell Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel Cardiovasc Res, October 1, 2000; 48(1): 44 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cice, E. Tagliamonte, L. Ferrara, and A. Iacono Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study Eur. Heart J., August 1, 2000; 21(15): 1259 - 1264. [Abstract] [PDF]
|
|
|
|
|
|
B. N. Singh and S. Doshi Maintaining Sinus Rhythm in Atrial Fibrillation by Drug Therapy: Single Agents or Combinations? Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 139 - 142. [PDF]
|
|
|
|
 |
|
 C. W. Hogue Jr and M. L. Hyder Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment Ann. Thorac. Surg., January 1, 2000; 69(1): 300 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Grace and A.J. Camm Voltage-gated calcium-channels and antiarrhythmic drug action Cardiovasc Res, January 1, 2000; 45(1): 43 - 51. [Full Text] [PDF]
|
|
|
|
|
|
W. Sun, J. S. M. Sarma, and B. N. Singh Electrophysiological Effects of Dronedarone (SR33589), a Noniodinated Benzofuran Derivative, in the Rabbit Heart : Comparison With Amiodarone Circulation, November 30, 1999; 100(22): 2276 - 2281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Merot, F. Charpentier, J.-M. Poirier, G. Coutris, and J. Weissenburger Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol Cardiovasc Res, November 1, 1999; 44(2): 303 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Sharma, J. S.M. Sarma, and B. N. Singh Effects of Sotalol on the Circadian Rhythmicity of Heart Rate and QT Intervals With a Noninvasive Index of Reverse-Use Dependency Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(1): 15 - 21. [Abstract] [PDF]
|
|
|
|
|
|
P. C. Deedwania, B. N. Singh, K. Ellenbogen, S. Fisher, R. Fletcher, and S. N. Singh Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation : Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Circulation, December 8, 1998; 98(23): 2574 - 2579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Credner, T. Klingenheben, O. Mauss, C. Sticherling, and S. H. Hohnloser Electrical storm in patients with transvenous implantable cardioverter-defibrillators: Incidence, management and prognostic implications J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1909 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-G. Li and S. H. Hohnloser Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control? Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 185 - 194. [Abstract] [PDF]
|
|
|
|
|
|
G. Cui, P. T. Sager, B. N. Singh, and L. Sen Different Effects of Amiodarone and Quinidine on the Homogeneity of Myocardial Refractoriness in Patients With Intraventricular Conduction Delay Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(3): 201 - 207. [Abstract] [PDF]
|
|
|
|
|
|
A. Matsumori, K. Ono, R. Nishio, Y. Nose, and S. Sasayama Amiodarone Inhibits Production of Tumor Necrosis Factor-{alpha} by Human Mononuclear Cells : A Possible Mechanism for its Effect in Heart Failure Circulation, September 2, 1997; 96(5): 1386 - 1389. [Abstract] [Full Text]
|
|
|
|
|
|
S. Sicouri, S. Moro, and M. V. Elizari d-Sotalol Induces Marked Action Potential Prolongation and Early Afterdepolarizations in M but Not Epicardial or Endocardial Cells of the Canine Ventricle Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(1): 27 - 37. [Abstract] [PDF]
|
|
|
|
|
|
B. N. Singh Searching for the Ideal Class III Antiarrhythmic Agent: How Pure Should They Be? Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 239 - 242. [PDF]
|
|
|
|
|
|
B. M. Massie, S. G. Fisher, P. C. Deedwania, B. N. Singh, R. D. Fletcher, and S. N. Singh Effect of Amiodarone on Clinical Status and Left Ventricular Function in Patients With Congestive Heart Failure Circulation, June 15, 1996; 93(12): 2128 - 2134. [Abstract] [Full Text]
|
|
|
|
|
|
B. N. Singh Antiarrhythmic Therapy of Ventricular Arrhythmias: The Contemporary Dilemma Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1996; 1(1): 3 - 7. [PDF]
|
|
|
|
|
|
A. van de Loo, T. Klingenheben, and S. H. Hohnloser Amiodarone Therapy After Previous Sotalol-induced Torsade de Pointes: Analysis of QT Dispersion to Predict Proarrhythmia Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1996; 1(1): 75 - 78. [Abstract] [PDF]
|
|
|
|
|
|
S. N. Singh, R. D. Fletcher, S. G. Fisher, B. N. Singh, H. D. Lewis, P. C. Deedwania, B. M. Massie, C. Colling, D. Lazzeri, and The Survival Trial of Antiarrhythmic Therapy in Co Amiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia N. Engl. J. Med., July 13, 1995; 333(2): 77 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O. Cheng and L. L. Mickleborough Amiodarone and Risk of Cardiac Operations Ann. Thorac. Surg., March 1, 1995; 59(3): 784 - 784. [Full Text]
|
|
Article
